This company listing is no longer active
H. Lundbeck Past Earnings Performance
Past criteria checks 0/6
Key information
-13.9%
Earnings growth rate
-14.0%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | -0.4% |
Return on equity | 6.0% |
Net Margin | 6.8% |
Next Earnings Update | 17 Aug 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How H. Lundbeck makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 22 | 16,398 | 1,109 | 6,768 | 3,884 |
31 Dec 21 | 16,299 | 1,318 | 6,625 | 3,820 |
30 Sep 21 | 16,521 | 1,873 | 6,698 | 3,634 |
30 Jun 21 | 16,971 | 1,965 | 6,680 | 3,578 |
31 Mar 21 | 17,381 | 2,110 | 6,720 | 2,999 |
31 Dec 20 | 17,672 | 1,581 | 6,912 | 3,753 |
30 Sep 20 | 17,818 | 904 | 6,812 | 3,760 |
30 Jun 20 | 17,490 | 1,242 | 6,744 | 3,538 |
31 Mar 20 | 17,366 | 1,507 | 6,672 | 4,039 |
31 Dec 19 | 17,036 | 2,313 | 6,413 | 3,116 |
30 Sep 19 | 16,811 | 3,091 | 6,212 | 3,214 |
30 Jun 19 | 17,309 | 3,395 | 6,143 | 3,302 |
31 Mar 19 | 17,766 | 3,606 | 6,061 | 3,313 |
31 Dec 18 | 18,117 | 3,907 | 6,039 | 3,277 |
30 Sep 18 | 18,313 | 3,806 | 6,120 | 3,069 |
30 Jun 18 | 18,028 | 3,627 | 6,174 | 2,903 |
31 Mar 18 | 17,608 | 3,236 | 6,298 | 2,765 |
31 Dec 17 | 17,234 | 2,624 | 6,482 | 2,705 |
30 Sep 17 | 17,007 | 2,544 | 6,428 | 2,769 |
30 Jun 17 | 16,607 | 1,988 | 6,462 | 2,839 |
31 Mar 17 | 16,075 | 1,612 | 6,424 | 2,887 |
31 Dec 16 | 15,634 | 1,211 | 6,293 | 2,967 |
30 Sep 16 | 15,202 | 290 | 6,475 | -1,979 |
30 Jun 16 | 14,923 | -1,289 | 7,320 | 3,196 |
31 Mar 16 | 14,801 | -5,427 | 7,573 | 3,095 |
31 Dec 15 | 14,594 | -5,694 | 7,762 | 3,097 |
30 Sep 15 | 14,108 | -5,879 | 7,814 | 8,003 |
Quality Earnings: LDB has a large one-off loss of DKK702.0M impacting its March 31 2022 financial results.
Growing Profit Margin: LDB's current net profit margins (6.8%) are lower than last year (12.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LDB's earnings have declined by 13.9% per year over the past 5 years.
Accelerating Growth: LDB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: LDB had negative earnings growth (-47.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.7%).
Return on Equity
High ROE: LDB's Return on Equity (6%) is considered low.